Amid Sun's FY16 earnings gloom, some little gems?
This article was originally published in Scrip
Executive Summary
While investors may at first glance be right in bludgeoning Sun Pharma's shares the day after a 20 July management update painted a grim picture on FY16 earnings, some analysts are also pointing to a clutch of "momentum catalysts" to keep an eye out for despite the ongoing challenges.